cur in more than 50% of patients with SLE.
INTRODUCTION
Intestinal pseudo-obstruction (IPO) is characterized by ineffective intestinal propulsion without mechanical or obstructive factors. Its clinical manifestations include nausea, vomiting, dysphagia, abdominal distension, abdominal pain, constipation, and weight loss. It is also characterized by sluggish or no audible bowel sounds and multiple air-fluid levels on abdominal radiography. 1 It may also be the primary or secondary manifestation of other diseases, including nervous, endocrine, and metabolic disorders, intra-abdominal inflammation, and connective tissue disease. 2 Systemic lupus erythematosus (SLE) is a multisystemic, autoimmune inflammatory disease of unknown etiology, and may affect any part of the gastrointestinal (GI) tract, from the mouth to the rectum. It has been reported that mild GI symptoms such as nausea, vomiting, and abdominal discomfort oc-www.irjournal.org
Laboratory test results showed a hemoglobin level of 11.0 g/dL, white blood cell count of 2,710/mm 3 (absolute neu- with speckled pattern) was positive. Anti-Ro antibody, antiLa antibody, and anti-Ro52 antibody (3+, 1+, 3+, respectively) were positive. Anti-Smith antibody, rheumatoid factor, anti-cardiolipin antibody, anti-b2-glycoprotein I (b2-GPI) antibody, and the direct Coombs test result were negative.
The urinalysis result was normal. The stool white blood cell count was 0−1/low-power field. Stool bacterial culture, and tests results for adenovirus, astrovirus, norovirus, enterovirus, and rotavirus by PCR were all negative. Marked gaseous dilatation and air-fluid levels were observed on plain abdominal radiography (Fig. 1A ). An abdominal and pelvic CT scan showed a small amount of ascites, mild intrahepatic duct dilatation, and marked distension of the small bowel without a definite obstructive lesion. No evidence of ureterohydronephrosis or peritonitis was observed (Fig. 1B) . She had no notable findings on esophagogastroduodenoscopy and colonoscopy. Capsule endoscopy was performed. No mucosal lesion in the small bowel was observed. Small bowel transit time was nearly 10 hours, and passage of the capsule occurred after 3 days. Despite several positive autoimmune serologic markers, clinical manifestations did not meet the diagnostic criteria for autoimmune diseases, such as systemic sclerosis, SLE, or Sjögren syndrome.
She had slight improvement with conservative care, including hydration and intravenous metoclopramide, throughout the 18-day hospitalization course. On the 14th day following discharge, she presented with recurrent nausea and abdominal distension. Severe small bowel dilatation and air-fluid levels were present on a plain abdominal radiography. Because we could not completely rule out the possibility of secondary IPO due to autoimmune diseases such as SLE, she was given oral prednisolone 40 mg/day (about 1 mg/kg) for 7 days. She stopped oral prednisolone because of adverse effects including suicidal ideation and hair loss. The oral steroid trial failed to improve the symptoms, as demonstrated on radiography (Fig. 1C) , and was discontinued. Oral pyridostigmine 60 mg/day was administered, but the radiographic finding did not improve. With oral prokinetics only, the ileus gradually improved on radiography (Fig. 1D ).
Forty-five days following discharge, she came to the hospital due to oral ulcers. Four months later, she developed arthralgias of the knees, elbows, wrists, and shoulders. She was finally diagnosed with SLE according to positive serology and overall clinical manifestations. Oral steroids were recommended but refused. She did take oral prokinetics and non-steroidal anti-inflammatory drugs (Table 1) .
DISCUSSION
IPO is characterized by ineffective intestinal propulsion resulting from impaired functioning of the visceral smooth muscle, enteric nerves, or visceral autonomic nervous system. 2 The classic symptoms of IPO include abdominal pain, abdominal distension, nausea, vomiting, alternating diarrhea and constipation, and weight loss. Paradoxically, both constipation and diarrhea may be observed in patients with IPO. Small bowel involvement may lead to bacterial overgrowth and steatorrhea, while predominant colonic involvement leads to constipation. [5] [6] [7] The diagnosis of IPO is made based on clinical aspects. Multiple air-fluid levels and small bowel dilatation, with or without thickened bowel wall, were observed on radiological imaging. esophagogastroduodenoscopy, colonoscopy, and abdominal CT are needed to exclude mechanical obstruction or elucidate other diseases. 3 Progressive systemic sclerosis, mixed connective tissue disease, and polymyositis/ dermatomyositis are known secondary causes of IPO. 8 IPO occurs in patients with SLE. [1] [2] [3] [4] 7, 8 It has also been reported that mild GI complications occur commonly in more than 50% of patients with SLE. 6,9 SLE may affect any part of the GI tract, from the mouth to the rectum. IPO is a rare GI manifestation of SLE. To our knowledge, there have been about 30 cases of IPO in SLE reported in the literature. As shown in the current case, it may also occur as the initial presentation of SLE (Table 2) . 4,10-15 Kim J and Kim N reported that a diagnosis of IPO was made in patients with SLE who underwent subtotal colectomy. 12 It would be possible to avoid unnecessary surgery if clinicians made a diagnosis of IPO in SLE at the earliest possible opportunity.
Little is known about the precise pathophysiology by which IPO occurs in patients with SLE, but there are numerous hypotheses. One is that IPO in SLE might be a late manifestation of immune-complex-mediated vasculitis. 8 16 However, no histopathologic evidence of vasculitis was found in some cases of IPO in SLE. 1, 17, 18 Another pathophysiological mechanism of IPO is an intrinsic muscle dysmotility. Postmortem examination showed an extensive fibrotic process in the muscularis layer without abnormality of innervation. 19 This might be a myogenic type of IPO.
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IPO can present with active lupus serologies. A previous study reported that the positive rates of anti-Ro (83.9%) and anti-La antibody (75%) are significantly higher in IPO than the usual prevalences of anti-Ro (30%) and anti-La antibody (10%) in SLE. 1 The current case presented with positive antiRo and anti-La antibody. Anti-proliferative cell nuclear antigen antibody was also more frequently detected in the patients with than in those without IPO. 20 However, no specific autoantibodies definitely related to IPO were found in the patients with SLE. It is necessary to identify specific antibodies that cause smooth muscle injury. Although the pathogenic mechanisms have not been clarified, high-dose steroids are helpful in improving the symptoms of IPO in SLE. 2, 7, 16 Intravenous methylprednisolone initiated at 1 mg/kg/day for 3 days, followed by oral prednisone 1 mg/kg/day resulted in a good clinical response in most cases. 2, 8 In this case, the therapeutic effect of oral prednisone could not be evaluated due to poor compliance induced by side effects. Immunosuppressants, such as azathioprine, 
